This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07900633 |
|---|---|
| Status | Not yet recruiting |
| Phase | Phase 3 |
| Sponsor | Eli Lilly and Company |
| Enrollment | 3,000 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Obesity; Overweight; Cardiovascular Diseases; Diabetes Mellitus, Type 2 |
| Interventions | Eloralintide; Placebo |
| Start | Dec 2026 |
| Primary completion | Nov 2029 |
| Study completion | Dec 2029 |
| Results posted | Not yet |
| Registry last updated | Oct 28, 2026 |
What the registry says the trial is about
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with a placebo in participants with obesity or overweight, type 2 diabetes, and increased cardiovascular risk.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Percent Change from Baseline in Body Weight | Baseline, Week 64 |
| Change from Baseline in Hemoglobin A1c (HbA1c) | Baseline, Week 36 |
9 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 1, 2026. See the trial changes feed for what has changed recently.
More from Eli Lilly and Company
- Eloralintide and Tirzepatide: Phase 3 Trial (NCT07881432)
- Eloralintide and Tirzepatide: Phase 3 Trial (NCT07881458)
- RENEW-MDD 1: Brenipatide, Phase 3 (NCT07412756)
- Retatrutide: Phase 3 Trial in Obesity (NCT07357415)
Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.
